Peptide Therapeutics, Medeva deal

MDV transferred to PTE a portfolio of non-injectable vaccine delivery technology for early-stage development. PTE will develop the clinical proof-of-principle for enterotoxigenic E. coli, typhoid and intranasal influenza vaccines. MDV holds an option to complete the late-stage development and to market any products arising from the development programs. ...